Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2 Myeloid 2 Lymphoid 1 Gastrointestinal 1

Conditions

Esophageal Neoplasms 1

Interventions

Oxaliplatin 1004 Fluorouracil 800 Capecitabine 765 Gemcitabine 651 Leucovorin 559 Irinotecan 537 Bevacizumab 513 Radiotherapy 460 Cisplatin 441 Drug Therapy 298 Cetuximab 280 Surgical Procedures, Operative 229 Paclitaxel 228 S 1 (combination) 218 pembrolizumab 206 Docetaxel 199 130-nm albumin-bound paclitaxel 196 Nivolumab 193 sintilimab 191 Radiosurgery 190 lenvatinib 181 Folfox protocol 179 Sorafenib 178 Albumin-Bound Paclitaxel 173 apatinib 170 tislelizumab 161 camrelizumab 160 Neoadjuvant Therapy 158 Blood Specimen Collection 154 durvalumab 148

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × eprenetapopt × Gastrointestinal × Clear all

NCT02999893 2021-12-13

APROC

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Terminated

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡